Investor Update – Q2 FY23 Test Volumes Rise 36% on Q2 FY22

Pacific Edge has today released its September Quarter Investor Update showing early signs that its investment in US sales and marketing initiatives are driving the adoption of its advanced genomic biomarker Cxbladder tests.

In the three months to the end of September (Q2 FY23) total test volumes processed in the company’s laboratories were 7,861 up 36% on the 5,780 tests processed in the same quarter of the prior year and up 11% on the 7,055 tests processed in the three months to the end of June 2022 (Q1 FY23).

Volumes for the quarter are 36% more than the average volumes recorded in the 2022 financial year. For the six months to the end of September 2022, Pacific Edge processed 14,916 tests in its laboratories, a figure that represents a 34% increase on the 11,136 tests processed in the same period in the prior financial year.

Further detail on test volumes is covered in the Investor Update.

View the Update